Showing results (1911-1920 of 2,138) with videos related to
Sort By:
Pageof 214
Blood Advances|November 30, 2021
Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemiaSydney Fobare, Jessica Kohlschmidt, Hatice Gulcin Ozer, et al.The British Journal of Dermatology|April 14, 2020
What is in? What is out? Updating the British Society for Cutaneous Allergy facial seriesS Rolls, E Owen, C G Bertram, et al.Blood|May 5, 2018
High <i>NPM1</i>-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AMLSanjay S Patel, Frank C Kuo, Christopher J Gibson, et al.Blood|June 5, 2004
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLJingrui Jiang, J Guillermo Paez, Jeffrey C Lee, et al.Blood|September 10, 2005
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domainFlorian Heidel, Fian K Solem, Frank Breitenbuecher, et al.Visual Neuroscience|December 8, 2005
Generation, characterization, and molecular cloning of the Noerg-1 mutation of rhodopsin in the mouseLawrence H Pinto, Martha H Vitaterna, Kazuhiro Shimomura, et al.Nature Genetics|May 31, 2001
Identification of the gene that, when mutated, causes the human obesity syndrome BBS4K Mykytyn, T Braun, R Carmi, et al.Leukemia|June 7, 2018
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcomeAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.Blood Advances|July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remissionSumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.American Journal of Hematology|November 10, 2017
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemiaDaniel J DeAngelo, Andrew M Brunner, Lillian Werner, et al.Pageof 214